KERX Financial Facts

Total operating expenses: 22.54M
Total research and development: 10.28M
See Full Income Statement

Goodwill: 3.21M
Total assets: 142.89M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 11/4/14 *Est. EPS Growth Rate -71.4% *Last Qtr.
Average EPS % Beat Rate -46.9% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +3.3% Normal Earnings Time N/A
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/7/14 Q214 -$0.24-$0.25 +$0.01N/AN/A N/A Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A Details
7/31/13 Q213 -$0.14-$0.10 -$0.04N/AN/A N/A Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A Details
3/11/13 Q412 -$0.09-$0.08 -$0.01N/AN/A N/A Details
11/8/12 Q312 -$0.08-$0.07 -$0.01N/AN/A N/A Details